FIELD: medicine.
SUBSTANCE: disclosed is a method of treating agitation and/or aggression, and/or associated symptoms in a patient with dementia, comprising administering deuterated dextromethorphan and quinidine to a patient in need thereof, where deuterated dextromethorphan is orally administered in amount of 10 mg to 200 mg per day and quinidine is orally administered in amount of 0.05 mg to 50 mg per day, and deuterated dextromethorphan and quinidine are administered in amounts sufficient to reduce a subject's score according to a modified Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS - CGIC) in relation to excitation of at least 0.5 times compared to subjects without treatment or subjects with the introduction of placebo, and/or to reduce the patient’s overall clinical assessment of changes (PGI-C) in relation to arousal by at least 0.6 times compared to untreated subjects or subjects when administered with placebo. Also disclosed is the use of deuterated dextromethorphan and quinidine for treating arousal and/or aggression and/or associated symptoms in a patient with dementia and using deuterated dextromethorphan and quinidine for preparing a drug for treating agitation and/or aggression, and/or related symptoms in a patient with dementia.
EFFECT: group of inventions provides treating excitement and/or aggression, and/or related symptoms in a patient with Alzheimer's disease, and said method has no increased risk of developing serious undesirable effects.
10 cl, 10 dwg, 16 tbl, 6 ex
